Abstract
Pharmacologic agents for CNS disorders are often inhibitors that occupy receptors, with frequent unavoidable side effects likely due to continuous binding. This review summarizes development of a novel aldehyde dehydrogenase 2 (ALDH2) inhibitor that specifically targets unique drug related episodic surges in dopamine (DA), a pathophysiologic mechanism that appears to underlie much of drug-seeking behavior. We have synthesized highly selective novel ALDH2 inhibitors (ALDH2i) that block alcohol- and cocaine cue-induced surges in nucleus accumbens (NAc) DA and prevent reinstatement of alcohol heavy drinking, cocaine self-administration and reinstatement of cocaine relapse-like behavior. The mechanism of action of ALDH2i depends on inhibiting dopamine aldehyde (DOPAL) clearance by ALDH2, enabling unmetabolized DOPAL to condense with DA to generate tetrahydropapaveroline (THP). THP selectively inhibits the activated (phosphorylated) tyrosine hydroxylase (TH) to suppress DA synthesis. Selective inhibition of ALDH2 appears to have therapeutic potential for treating cue-induced drug relapse, a major unmet need for treating addicted subjects.
Keywords: Addiction, alcohol, ALDH2, cocaine, craving, relapse.
CNS & Neurological Disorders - Drug Targets
Title:From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction
Volume: 14 Issue: 6
Author(s): Ivan Diamond and Lina Yao
Affiliation:
Keywords: Addiction, alcohol, ALDH2, cocaine, craving, relapse.
Abstract: Pharmacologic agents for CNS disorders are often inhibitors that occupy receptors, with frequent unavoidable side effects likely due to continuous binding. This review summarizes development of a novel aldehyde dehydrogenase 2 (ALDH2) inhibitor that specifically targets unique drug related episodic surges in dopamine (DA), a pathophysiologic mechanism that appears to underlie much of drug-seeking behavior. We have synthesized highly selective novel ALDH2 inhibitors (ALDH2i) that block alcohol- and cocaine cue-induced surges in nucleus accumbens (NAc) DA and prevent reinstatement of alcohol heavy drinking, cocaine self-administration and reinstatement of cocaine relapse-like behavior. The mechanism of action of ALDH2i depends on inhibiting dopamine aldehyde (DOPAL) clearance by ALDH2, enabling unmetabolized DOPAL to condense with DA to generate tetrahydropapaveroline (THP). THP selectively inhibits the activated (phosphorylated) tyrosine hydroxylase (TH) to suppress DA synthesis. Selective inhibition of ALDH2 appears to have therapeutic potential for treating cue-induced drug relapse, a major unmet need for treating addicted subjects.
Export Options
About this article
Cite this article as:
Diamond Ivan and Yao Lina, From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150529144329
DOI https://dx.doi.org/10.2174/1871527314666150529144329 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Letters in Drug Design & Discovery Vasculitis Following Influenza Vaccination: A Review of the Literature
Current Rheumatology Reviews Is Alzheimers Disease a Myth? When is Disease a Disease?
Current Alzheimer Research The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Emerging Role of TRP Channels in Mechanisms of Temperature and Pain Sensation
Current Neuropharmacology Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
CNS & Neurological Disorders - Drug Targets Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design IL28B Polymorphism, Blood Interferon-Alpha Concentration, and Disease Stage of HCV Mono-Infected and HCV-HIV Co-Infected Patients
Current HIV Research Cannabinoids, Opioids and MDMA: Neuropsychological Interactions Related to Addiction
Current Drug Targets The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Putative Immune Regulatory Role of Statins
Current Immunology Reviews (Discontinued) Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Accelerated Fibrillation of α-Synuclein Induced by the Combined Action of Macromolecular Crowding and Factors Inducing Partial Folding
Current Alzheimer Research Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Remifentanil with or without Propofol as Anesthesia Agents for Trans- Vaginal Ultrasonography Oocyte Retrieval (TUGOR) on Pregnancy and Anesthesia Outcomes: A Randomized Controlled Trial
Current Reviews in Clinical and Experimental Pharmacology Alzheimer Treatment by Applying Ultrasound Waves
Current Signal Transduction Therapy Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Neuropharmacology MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry